Home › B-Cell Lymphoma
B-Cell Lymphoma clinical trials recruiting in the U.S.
68 studies for B-Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY17 studies
- Houston, TX16 studies
- Chicago, IL13 studies
- Nashville, TN12 studies
- Philadelphia, PA11 studies
- Rochester, MN10 studies
- Milwaukee, WI10 studies
- Boston, MA10 studies
- Baldwin Park, CA9 studies
- Cleveland, OH8 studies
- Salt Lake City, UT8 studies
- Seattle, WA8 studies
- Pittsburgh, PA7 studies
- Columbus, OH7 studies
- Los Angeles, CA7 studies
- Atlanta, GA7 studies
- Aurora, CO7 studies
- Washington, DC7 studies
- Dallas, TX7 studies
- Denver, CO7 studies
- Charlotte, NC6 studies
- San Antonio, TX6 studies
- Edison, NJ6 studies
- New Haven, CT6 studies
- Cincinnati, OH6 studies
- Mountain View, CA6 studies
- Portland, OR5 studies
- Ann Arbor, MI5 studies
- Richmond, VA5 studies
- Winston-Salem, NC5 studies
- St. Louis, MO5 studies
- Omaha, NE5 studies
- Kansas City, MO5 studies
- Jacksonville, FL4 studies
- Tampa, FL4 studies
- Miami, FL4 studies
- Louisville, KY4 studies
- Irvine, CA4 studies
- Cedar Rapids, IA4 studies
- Indianapolis, IN4 studies
By state
- Arizona5 studies
- California22 studies
- Colorado12 studies
- Connecticut6 studies
- District of Columbia3 studies
- Florida15 studies
- Georgia9 studies
- Illinois13 studies
- Indiana5 studies
- Iowa6 studies
- Kansas10 studies
- Kentucky4 studies
- Maryland7 studies
- Massachusetts10 studies
- Michigan8 studies
- Minnesota12 studies
- Missouri5 studies
- Nebraska5 studies
- New Jersey10 studies
- New York19 studies
- North Carolina10 studies
- Ohio17 studies
- Oregon6 studies
- Pennsylvania16 studies
- Tennessee14 studies
- Texas26 studies
- Utah8 studies
- Virginia8 studies
- Washington11 studies
- Wisconsin11 studies
Recently updated studies
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Nov 13, 2026 · NCT06173518A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05773040Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05272384BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT05370430A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07735533A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07188558Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07283679A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06213311Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07520006A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07123454A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606Family Study of Lymphoproliferative Disorders
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Nov 2, 2026 · NCT00626496A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06742996Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06564038CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RecruitingPhase 1/2
Ages 3 to 39 · All sexes · Updated Oct 26, 2026 · NCT05442515GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07711483Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 22, 2026 · NCT06052826Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07097363Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07532525A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06528301Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06526793Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Recruiting
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05940272CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06026319From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.